Funds › TCG Crossover Management, LLC
TCG Crossover Management, LLC
13F for Q2 2026, filed Aug 14, 2026. 54 positions worth $4.2B.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of TCG Crossover Management, LLC in the latest 13F quarter?
Using 13F.ai, how has TCG Crossover Management, LLC's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of TCG Crossover Management, LLC's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q2 2026
Largest first. Common shares only; puts and calls are under All positions.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | ABVX Abivax SA · ADR | 6.01M | $800.6M | 19.2% | -7.3% | 13F ↗ |
| 2 | TNGX Tango Therapeutics, Inc. | 9.08M | $283.9M | 6.8% | -13.8% | 13F ↗ |
| 3 | CGON CG Oncology, Inc. | 3.67M | $260.8M | 6.3% | Unchanged | 13F ↗ |
| 4 | COGT Cogent Biosciences, Inc. | 4.85M | $187.9M | 4.5% | -1.9% | 13F ↗ |
| 5 | IMVT Immunovant, Inc. | 4.46M | $171.8M | 4.1% | Unchanged | 13F ↗ |
| 6 | SYRE Spyre Therapeutics, Inc. | 1.90M | $168.7M | 4.1% | Unchanged | 13F ↗ |
| 7 | DNTH Dianthus Therapeutics, Inc. | 1.68M | $163.4M | 3.9% | Unchanged | 13F ↗ |
| 8 | MIRM Mirum Pharmaceuticals, Inc. | 1.06M | $124.3M | 3.0% | Unchanged | 13F ↗ |
| 9 | ZLAB Zai Lab Limited · ADR | 6.14M | $116.6M | 2.8% | New | 13F ↗ |
| 10 | AMLX Amylyx Pharmaceuticals, Inc. | 6.24M | $112.1M | 2.7% | Unchanged | 13F ↗ |
| 11 | GLUE Monte Rosa Therapeutics, Inc. | 4.62M | $111.9M | 2.7% | Unchanged | 13F ↗ |
| 12 | BCRX BioCryst Pharmaceuticals, Inc. | 11.02M | $110.2M | 2.6% | Unchanged | 13F ↗ |
| 13 | VOR Vor Biopharma Inc. | 5.67M | $104.4M | 2.5% | Unchanged | 13F ↗ |
| 14 | TYRA Tyra Biosciences, Inc. | 3.25M | $103.8M | 2.5% | Unchanged | 13F ↗ |
| 15 | DYN Dyne Therapeutics, Inc. | 4.62M | $102.5M | 2.5% | Unchanged | 13F ↗ |
| 16 | IRON Disc Medicine, Inc. | 1.34M | $98.1M | 2.4% | Unchanged | 13F ↗ |
| 17 | RLAY Relay Therapeutics, Inc. | 4.27M | $80.0M | 1.9% | Unchanged | 13F ↗ |
| 18 | SVRA Savara, Inc. | 12.36M | $76.2M | 1.8% | Unchanged | 13F ↗ |
| 19 | AURA Aura Biosciences, Inc. | 9.53M | $67.7M | 1.6% | New | 13F ↗ |
| 20 | RVMD Revolution Medicines, Inc. | 340,899 | $63.8M | 1.5% | -40.9% | 13F ↗ |
| 21 | TRAX First Tracks Biotherapeutics, Inc. · Ord Shs *A* | 2.90M | $58.3M | 1.4% | New | 13F ↗ |
| 22 | KOD Kodiak Sciences Inc | 1.45M | $56.3M | 1.4% | Unchanged | 13F ↗ |
| 23 | AVTX Avalo Therapeutics, Inc. | 3.02M | $55.8M | 1.3% | +309% | 13F ↗ |
| 24 | LBRX LB Pharmaceuticals Inc | 1.45M | $47.0M | 1.1% | -21.3% | 13F ↗ |
| 25 | IPSC Century Therapeutics, Inc. | 17.75M | $43.4M | 1.0% | Unchanged | 13F ↗ |
| 26 | TECX Tectonic Therapeutic, Inc. | 1.20M | $41.4M | 1.0% | Unchanged | 13F ↗ |
| 27 | XNCR Xencor, Inc. | 2.45M | $39.5M | 0.9% | Unchanged | 13F ↗ |
| 28 | SRZN Surrozen, Inc. | 1.47M | $38.2M | 0.9% | Unchanged | 13F ↗ |
| 29 | EDIT Editas Medicine, Inc. | 11.11M | $36.0M | 0.9% | New | 13F ↗ |
| 30 | MBX MBX Biosciences, Inc. | 650,000 | $35.9M | 0.9% | Unchanged | 13F ↗ |
| 31 | PHVS Pharvaris N.V. | 1.01M | $34.9M | 0.8% | New | 13F ↗ |
| 32 | SLN Silence Therapeutics Plc · ADR | 3.03M | $33.3M | 0.8% | Unchanged | 13F ↗ |
| 33 | IFRX InflaRx N.V. | 14.50M | $32.5M | 0.8% | New | 13F ↗ |
| 34 | ALT Altimmune, Inc. | 10.00M | $30.4M | 0.7% | New | 13F ↗ |
| 35 | JANX Janux Therapeutics, Inc. | 1.79M | $27.5M | 0.7% | Unchanged | 13F ↗ |
| 36 | CATX Perspective Therapeutics, Inc. | 7.92M | $27.0M | 0.6% | Unchanged | 13F ↗ |
| 37 | AGMB AgomAb Therapeutics NV · ADR | 2.05M | $26.7M | 0.6% | Unchanged | 13F ↗ |
| 38 | BHVN Biohaven Ltd. | 1.78M | $26.5M | 0.6% | -61.6% | 13F ↗ |
| 39 | AKTS Aktis Oncology, Inc. | 696,560 | $22.5M | 0.5% | New | 13F ↗ |
| 40 | ALEC Alector, Inc. | 10.00M | $20.1M | 0.5% | Unchanged | 13F ↗ |
| 41 | Forte Biosciences Inc | 920,000 | $19.6M | 0.5% | New | 13F ↗ |
| 42 | MNPR Monopar Therapeutics Inc. | 203,327 | $18.8M | 0.5% | +53.9% | 13F ↗ |
| 43 | OCUL Ocular Therapeutix, Inc. | 1.65M | $16.2M | 0.4% | Unchanged | 13F ↗ |
| 44 | ADCT ADC Therapeutics SA | 11.39M | $12.2M | 0.3% | Unchanged | 13F ↗ |
| 45 | ALXO ALX Oncology Holdings Inc. | 5.66M | $11.7M | 0.3% | -56.5% | 13F ↗ |
| 46 | TRDA Entrada Therapeutics, Inc. | 1.06M | $7.8M | 0.2% | -53.7% | 13F ↗ |
| 47 | CGEM Cullinan Therapeutics, Inc. | 406,786 | $7.4M | 0.2% | Unchanged | 13F ↗ |
| 48 | ARVN Arvinas, Inc. | 707,098 | $5.9M | 0.1% | -70.4% | 13F ↗ |
| 49 | KRRO Korro Bio, Inc. | 416,301 | $5.5M | 0.1% | Unchanged | 13F ↗ |
| 50 | RACC Research Alliance Corporation III | 500,000 | $5.3M | 0.1% | New | 13F ↗ |
Changes since Q1 2026
12 new, 2 added to, 9 trimmed, 7 exited, 31 unchanged. By estimated dollars.
New positions (12)
| ZLAB Zai Lab Limited · ADR | 6.14M | New | $116.6M |
| AURA Aura Biosciences, Inc. | 9.53M | New | $67.7M |
| TRAX First Tracks Biotherapeutics, Inc. · Ord Shs *A* | 2.90M | New | $58.3M |
| EDIT Editas Medicine, Inc. | 11.11M | New | $36.0M |
| PHVS Pharvaris N.V. | 1.01M | New | $34.9M |
| IFRX InflaRx N.V. | 14.50M | New | $32.5M |
| ALT Altimmune, Inc. | 10.00M | New | $30.4M |
| AKTS Aktis Oncology, Inc. | 696,560 | New | $22.5M |
| Forte Biosciences Inc | 920,000 | New | $19.6M |
| RACC Research Alliance Corporation III | 500,000 | New | $5.3M |
Added to (2)
Trimmed (9)
| ABVX Abivax SA · ADR | 6.01M | -7.3% | -$63.1M |
| TNGX Tango Therapeutics, Inc. | 9.08M | -13.8% | -$45.3M |
| RVMD Revolution Medicines, Inc. | 340,899 | -40.9% | -$44.1M |
| BHVN Biohaven Ltd. | 1.78M | -61.6% | -$42.4M |
| ALXO ALX Oncology Holdings Inc. | 5.66M | -56.5% | -$15.2M |
| ARVN Arvinas, Inc. | 707,098 | -70.4% | -$14.0M |
| LBRX LB Pharmaceuticals Inc | 1.45M | -21.3% | -$12.7M |
| TRDA Entrada Therapeutics, Inc. | 1.06M | -53.7% | -$9.0M |
| COGT Cogent Biosciences, Inc. | 4.85M | -1.9% | -$3.6M |
Exited (7)
| Centessa Pharmaceuticals plc ADR | 4.29M | Exited | -$170.3M |
| FULC Fulcrum Therapeutics, Inc. | 5.25M | Exited | -$40.3M |
| LQDA Liquidia Corporation | 403,048 | Exited | -$15.2M |
| URGN UroGen Pharma Ltd. | 405,365 | Exited | -$7.3M |
| GPCR Structure Therapeutics Inc. | 140,411 | Exited | -$6.8M |
| UPB Upstream Bio, Inc. | 181,063 | Exited | -$1.6M |
| VTGN Vistagen Therapeutics, Inc. | 2.68M | Exited | -$1.5M |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
All positions
Search, sort and filter every position, with puts and calls on their own tab. Premium plan.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q2 2026.
Filings
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer